Trevena Inc. Stock
Trevena Inc. Stock
Pros and Cons of Trevena Inc. in the next few years
Pros
Cons
Performance of Trevena Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Trevena Inc. | -4.370% | -6.676% | -6.143% | -40.811% | -46.236% | -99.061% | -98.946% |
| Ardelyx Inc. | 28.120% | 34.723% | 18.969% | 89.624% | 39.758% | 44.250% | - |
| Evolus Inc | 10.280% | 12.381% | -5.600% | 60.544% | 30.387% | 60.544% | - |
| Salarius Pharmaceuticals Inc. | 11.650% | 7.981% | 17.949% | -67.606% | -17.117% | -98.248% | -99.993% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Trevena Inc. (TRVN) is a biotechnology and medical research company that has shown mixed financial stability in recent years. As a financial analyst, it is essential to dissect their financial statements for a deeper understanding of the company's current financial health and future prospects.
Increase in gross profit: The company experienced a jump in gross profit from 2020 to 2021 while struggling slightly in the first quarter of 2023. This indicates that the company might be managing its cost of revenue efficiently and effectively.
Decrease in research and development expenses: Trevena's R&D expenses have been on the decline since 2020, illustrating that the company might be streamlining its research efforts and possibly moving closer to marketing its products.
Comments